| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.022 | 0.9 |
| mRNA | Panobinostat | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |